De Giorgi, Ugo http://orcid.org/0000-0001-7520-2908
Sansovini, Maddalena
Severi, Stefano
Nicolini, Silvia
Monti, Manuela
Gurioli, Giorgia
Foca, Flavia
Casadei, Chiara http://orcid.org/0000-0003-2467-749X
Conteduca, Vincenza http://orcid.org/0000-0002-6921-714X
Celli, Monica
Di Iorio, Valentina
Calistri, Daniele
Matteucci, Federica
von Eyben, Finn Edler
Attard, Gerhardt
Paganelli, Giovanni
Funding for this research was provided by:
Cancer Research UK (A22744, C416/A26822)
Article History
Received: 4 February 2021
Revised: 21 June 2021
Accepted: 21 July 2021
First Online: 31 July 2021
Ethics approval and consent to participate
: Written informed consent was obtained from each patient prior to entry into the study. The study was conducted in compliance with the principles of the Declaration of Helsinki and local ethical and legal requirements. The protocol and informed consent were approved by the Institutional Review Board of Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), Meldola, Italy (NCT03454750).
: UDG reports honoraria, consulting fees, or travel support from Merck, Bristol Myers Squibb, Janssen, Pfizer, Novartis, Astellas, Bayer, Sanofi, and Novartis and grant support from Merck and Amgen. VC reports honoraria, consulting fees, or travel support Bayer, Astellas, Janssen-Cilag, and Sanofi-Aventis. GA certifies that all conflicts of interest, including specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the manuscript (e.g. employment/affiliation, grants or funding, consultancies, honoraria, stock ownership or options, expert testimony, royalties, or patents filed, received, or pending), are the following: GA reports receiving commercial research grants from Janssen, Arno Therapeutics, and Innocrin Pharma; has received honoraria and/or travel support from the speakers’ bureaus of Janssen, Astellas, Sanofi-Aventis, and Roche/Ventana; has received travel support from Pfizer, Abbott Laboratories, Bayer Healthcare, and Essa Pharmaceuticals; has ownership interest (including patents) in The Institute of Cancer Research Rewards to Inventors; and is a consultant for/advisory board member of Janssen-Cilag, Veridex, Bayer Healthcare, Roche/Ventana, Astellas, Medivation, Pfizer, Novartis, Millennium Pharma, Abbott Laboratories, and Essa Pharma.